Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Veterinary Anti Infective Market

ID: MRFR/HC/40574-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Veterinary Anti-Infective Market Research Report By Drug Type (Antibiotics, Antifungals, Antiparasitics, Vaccines), By Animal Type (Livestock, Pets, Aquaculture, Poultry), By Route of Administration (Oral, Injectable, Topical, Inhalation), By Formulation Type (Powder, Liquid, Solid, Injectable) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Veterinary Anti Infective Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Drug Type (USD Billion)
  49.     4.1.1 Antibiotics
  50.     4.1.2 Antifungals
  51.     4.1.3 Antiparasitics
  52.     4.1.4 Vaccines
  53.   4.2 Healthcare, BY Animal Type (USD Billion)
  54.     4.2.1 Livestock
  55.     4.2.2 Pets
  56.     4.2.3 Aquaculture
  57.     4.2.4 Poultry
  58.   4.3 Healthcare, BY Route of Administration (USD Billion)
  59.     4.3.1 Oral
  60.     4.3.2 Injectable
  61.     4.3.3 Topical
  62.     4.3.4 Inhalation
  63.   4.4 Healthcare, BY Formulation Type (USD Billion)
  64.     4.4.1 Powder
  65.     4.4.2 Liquid
  66.     4.4.3 Solid
  67.     4.4.4 Injectable
  68.   4.5 Healthcare, BY Region (USD Billion)
  69.     4.5.1 North America
  70.       4.5.1.1 US
  71.       4.5.1.2 Canada
  72.     4.5.2 Europe
  73.       4.5.2.1 Germany
  74.       4.5.2.2 UK
  75.       4.5.2.3 France
  76.       4.5.2.4 Russia
  77.       4.5.2.5 Italy
  78.       4.5.2.6 Spain
  79.       4.5.2.7 Rest of Europe
  80.     4.5.3 APAC
  81.       4.5.3.1 China
  82.       4.5.3.2 India
  83.       4.5.3.3 Japan
  84.       4.5.3.4 South Korea
  85.       4.5.3.5 Malaysia
  86.       4.5.3.6 Thailand
  87.       4.5.3.7 Indonesia
  88.       4.5.3.8 Rest of APAC
  89.     4.5.4 South America
  90.       4.5.4.1 Brazil
  91.       4.5.4.2 Mexico
  92.       4.5.4.3 Argentina
  93.       4.5.4.4 Rest of South America
  94.     4.5.5 MEA
  95.       4.5.5.1 GCC Countries
  96.       4.5.5.2 South Africa
  97.       4.5.5.3 Rest of MEA
  98. 5 SECTION V: COMPETITIVE ANALYSIS
  99.   5.1 Competitive Landscape
  100.     5.1.1 Overview
  101.     5.1.2 Competitive Analysis
  102.     5.1.3 Market share Analysis
  103.     5.1.4 Major Growth Strategy in the Healthcare
  104.     5.1.5 Competitive Benchmarking
  105.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  106.     5.1.7 Key developments and growth strategies
  107.       5.1.7.1 New Product Launch/Service Deployment
  108.       5.1.7.2 Merger & Acquisitions
  109.       5.1.7.3 Joint Ventures
  110.     5.1.8 Major Players Financial Matrix
  111.       5.1.8.1 Sales and Operating Income
  112.       5.1.8.2 Major Players R&D Expenditure. 2023
  113.   5.2 Company Profiles
  114.     5.2.1 Zoetis (US)
  115.       5.2.1.1 Financial Overview
  116.       5.2.1.2 Products Offered
  117.       5.2.1.3 Key Developments
  118.       5.2.1.4 SWOT Analysis
  119.       5.2.1.5 Key Strategies
  120.     5.2.2 Boehringer Ingelheim (DE)
  121.       5.2.2.1 Financial Overview
  122.       5.2.2.2 Products Offered
  123.       5.2.2.3 Key Developments
  124.       5.2.2.4 SWOT Analysis
  125.       5.2.2.5 Key Strategies
  126.     5.2.3 Merck Animal Health (US)
  127.       5.2.3.1 Financial Overview
  128.       5.2.3.2 Products Offered
  129.       5.2.3.3 Key Developments
  130.       5.2.3.4 SWOT Analysis
  131.       5.2.3.5 Key Strategies
  132.     5.2.4 Elanco Animal Health (US)
  133.       5.2.4.1 Financial Overview
  134.       5.2.4.2 Products Offered
  135.       5.2.4.3 Key Developments
  136.       5.2.4.4 SWOT Analysis
  137.       5.2.4.5 Key Strategies
  138.     5.2.5 Virbac (FR)
  139.       5.2.5.1 Financial Overview
  140.       5.2.5.2 Products Offered
  141.       5.2.5.3 Key Developments
  142.       5.2.5.4 SWOT Analysis
  143.       5.2.5.5 Key Strategies
  144.     5.2.6 Ceva Santé Animale (FR)
  145.       5.2.6.1 Financial Overview
  146.       5.2.6.2 Products Offered
  147.       5.2.6.3 Key Developments
  148.       5.2.6.4 SWOT Analysis
  149.       5.2.6.5 Key Strategies
  150.     5.2.7 Dechra Pharmaceuticals (GB)
  151.       5.2.7.1 Financial Overview
  152.       5.2.7.2 Products Offered
  153.       5.2.7.3 Key Developments
  154.       5.2.7.4 SWOT Analysis
  155.       5.2.7.5 Key Strategies
  156.     5.2.8 Phibro Animal Health (US)
  157.       5.2.8.1 Financial Overview
  158.       5.2.8.2 Products Offered
  159.       5.2.8.3 Key Developments
  160.       5.2.8.4 SWOT Analysis
  161.       5.2.8.5 Key Strategies
  162.     5.2.9 Heska Corporation (US)
  163.       5.2.9.1 Financial Overview
  164.       5.2.9.2 Products Offered
  165.       5.2.9.3 Key Developments
  166.       5.2.9.4 SWOT Analysis
  167.       5.2.9.5 Key Strategies
  168.   5.3 Appendix
  169.     5.3.1 References
  170.     5.3.2 Related Reports
  171. 6 LIST OF FIGURES
  172.   6.1 MARKET SYNOPSIS
  173.   6.2 NORTH AMERICA MARKET ANALYSIS
  174.   6.3 US MARKET ANALYSIS BY DRUG TYPE
  175.   6.4 US MARKET ANALYSIS BY ANIMAL TYPE
  176.   6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  177.   6.6 US MARKET ANALYSIS BY FORMULATION TYPE
  178.   6.7 CANADA MARKET ANALYSIS BY DRUG TYPE
  179.   6.8 CANADA MARKET ANALYSIS BY ANIMAL TYPE
  180.   6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  181.   6.10 CANADA MARKET ANALYSIS BY FORMULATION TYPE
  182.   6.11 EUROPE MARKET ANALYSIS
  183.   6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE
  184.   6.13 GERMANY MARKET ANALYSIS BY ANIMAL TYPE
  185.   6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  186.   6.15 GERMANY MARKET ANALYSIS BY FORMULATION TYPE
  187.   6.16 UK MARKET ANALYSIS BY DRUG TYPE
  188.   6.17 UK MARKET ANALYSIS BY ANIMAL TYPE
  189.   6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  190.   6.19 UK MARKET ANALYSIS BY FORMULATION TYPE
  191.   6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE
  192.   6.21 FRANCE MARKET ANALYSIS BY ANIMAL TYPE
  193.   6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  194.   6.23 FRANCE MARKET ANALYSIS BY FORMULATION TYPE
  195.   6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE
  196.   6.25 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE
  197.   6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  198.   6.27 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE
  199.   6.28 ITALY MARKET ANALYSIS BY DRUG TYPE
  200.   6.29 ITALY MARKET ANALYSIS BY ANIMAL TYPE
  201.   6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  202.   6.31 ITALY MARKET ANALYSIS BY FORMULATION TYPE
  203.   6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE
  204.   6.33 SPAIN MARKET ANALYSIS BY ANIMAL TYPE
  205.   6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  206.   6.35 SPAIN MARKET ANALYSIS BY FORMULATION TYPE
  207.   6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE
  208.   6.37 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE
  209.   6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  210.   6.39 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE
  211.   6.40 APAC MARKET ANALYSIS
  212.   6.41 CHINA MARKET ANALYSIS BY DRUG TYPE
  213.   6.42 CHINA MARKET ANALYSIS BY ANIMAL TYPE
  214.   6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  215.   6.44 CHINA MARKET ANALYSIS BY FORMULATION TYPE
  216.   6.45 INDIA MARKET ANALYSIS BY DRUG TYPE
  217.   6.46 INDIA MARKET ANALYSIS BY ANIMAL TYPE
  218.   6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  219.   6.48 INDIA MARKET ANALYSIS BY FORMULATION TYPE
  220.   6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE
  221.   6.50 JAPAN MARKET ANALYSIS BY ANIMAL TYPE
  222.   6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  223.   6.52 JAPAN MARKET ANALYSIS BY FORMULATION TYPE
  224.   6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE
  225.   6.54 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE
  226.   6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  227.   6.56 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE
  228.   6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE
  229.   6.58 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE
  230.   6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  231.   6.60 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE
  232.   6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE
  233.   6.62 THAILAND MARKET ANALYSIS BY ANIMAL TYPE
  234.   6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  235.   6.64 THAILAND MARKET ANALYSIS BY FORMULATION TYPE
  236.   6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE
  237.   6.66 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE
  238.   6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  239.   6.68 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE
  240.   6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE
  241.   6.70 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE
  242.   6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  243.   6.72 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE
  244.   6.73 SOUTH AMERICA MARKET ANALYSIS
  245.   6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE
  246.   6.75 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE
  247.   6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  248.   6.77 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE
  249.   6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE
  250.   6.79 MEXICO MARKET ANALYSIS BY ANIMAL TYPE
  251.   6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  252.   6.81 MEXICO MARKET ANALYSIS BY FORMULATION TYPE
  253.   6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE
  254.   6.83 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE
  255.   6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  256.   6.85 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE
  257.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
  258.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE
  259.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  260.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
  261.   6.90 MEA MARKET ANALYSIS
  262.   6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE
  263.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE
  264.   6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  265.   6.94 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE
  266.   6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE
  267.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE
  268.   6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  269.   6.98 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE
  270.   6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE
  271.   6.100 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE
  272.   6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  273.   6.102 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE
  274.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  275.   6.104 RESEARCH PROCESS OF MRFR
  276.   6.105 DRO ANALYSIS OF HEALTHCARE
  277.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  278.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  279.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  280.   6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
  281.   6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
  282.   6.111 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE)
  283.   6.112 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion)
  284.   6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  285.   6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  286.   6.115 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  287.   6.116 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
  288.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  289. 7 LIST OF TABLES
  290.   7.1 LIST OF ASSUMPTIONS
  291.     7.1.1
  292.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  293.     7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  294.     7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  295.     7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  296.     7.2.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  297.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  298.     7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  299.     7.3.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  300.     7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  301.     7.3.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  302.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  303.     7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  304.     7.4.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  305.     7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  306.     7.4.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  307.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  308.     7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  309.     7.5.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  310.     7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  311.     7.5.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  312.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  313.     7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  314.     7.6.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  315.     7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  316.     7.6.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  317.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  318.     7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  319.     7.7.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  320.     7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  321.     7.7.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  322.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  323.     7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  324.     7.8.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  325.     7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  326.     7.8.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  327.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  328.     7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  329.     7.9.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  330.     7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  331.     7.9.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  332.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  333.     7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  334.     7.10.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  335.     7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  336.     7.10.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  337.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  338.     7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  339.     7.11.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  340.     7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  341.     7.11.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  342.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  343.     7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  344.     7.12.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  345.     7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  346.     7.12.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  347.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  348.     7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  349.     7.13.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  350.     7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  351.     7.13.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  352.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  353.     7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  354.     7.14.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  355.     7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  356.     7.14.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  357.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  358.     7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  359.     7.15.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  360.     7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  361.     7.15.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  362.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  363.     7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  364.     7.16.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  365.     7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  366.     7.16.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  367.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  368.     7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  369.     7.17.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  370.     7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  371.     7.17.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  372.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  373.     7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  374.     7.18.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  375.     7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  376.     7.18.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  377.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  378.     7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  379.     7.19.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  380.     7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  381.     7.19.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  382.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  383.     7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  384.     7.20.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  385.     7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  386.     7.20.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  387.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  388.     7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  389.     7.21.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  390.     7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  391.     7.21.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  392.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  393.     7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  394.     7.22.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  395.     7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  396.     7.22.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  397.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  398.     7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  399.     7.23.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  400.     7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  401.     7.23.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  402.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  403.     7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  404.     7.24.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  405.     7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  406.     7.24.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  407.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  408.     7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  409.     7.25.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  410.     7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  411.     7.25.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  412.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  413.     7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  414.     7.26.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  415.     7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  416.     7.26.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  417.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  418.     7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  419.     7.27.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  420.     7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  421.     7.27.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  422.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  423.     7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  424.     7.28.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  425.     7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  426.     7.28.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  427.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  428.     7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  429.     7.29.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  430.     7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  431.     7.29.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  432.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  433.     7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  434.     7.30.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  435.     7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  436.     7.30.4 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  437.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  438.     7.31.1
  439.   7.32 ACQUISITION/PARTNERSHIP
  440.     7.32.1

Healthcare Market Segmentation

Healthcare By Drug Type (USD Billion, 2025-2035)

  • Antibiotics
  • Antifungals
  • Antiparasitics
  • Vaccines

Healthcare By Animal Type (USD Billion, 2025-2035)

  • Livestock
  • Pets
  • Aquaculture
  • Poultry

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Injectable
  • Topical
  • Inhalation

Healthcare By Formulation Type (USD Billion, 2025-2035)

  • Powder
  • Liquid
  • Solid
  • Injectable

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions